Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlloCAR-T in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
NCT06080191Phase 1Recruiting
- Start
- Apr 2024
- Primary completion
- Jun 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD19-CAR-Lenti-ALLO in B cell acute lymphoblastic leukemia (B-ALL). Primary endpoint: Dose Limiting Toxicity at 28 days. Started Apr 2024; status: recruiting.
02
Drugs
CD19-CAR-Lenti-ALLO
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06080191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06080191.